Global Connected Drug Delivery Devices Market Poised for Robust Expansion, Reaching USD 5.08 Billion by 2032, estimates DelveInsight

The global Connected Drug Delivery Devices Market is set to witness significant growth over the coming decade, driven by the escalating burden of chronic diseases, rising digital health adoption, and rapid technological advancements in smart therapeutic delivery. According to the latest market assessment, the global connected drug delivery devices market size valued at USD 986.91 million in 2024 is projected to reach USD 5,087.57 million by 2032, growing at a CAGR of 23.17% from 2025 to 2032. North America is expected to lead the market, while the Asia-Pacific region is poised to emerge as the fastest-growing market during the forecast period.
Connected drug delivery devices integrate traditional drug administration systems with sensors, wireless connectivity, digital interfaces, and data analytics to enable real-time monitoring, enhance medication adherence, and support patient-centric treatment. These devices leverage technologies such as Bluetooth, Near-Field Communication (NFC), and cloud-based platforms, making therapy management more accurate, personalized, and accessible.

To know more about why North America is leading the market growth in the Connected Drug Delivery Devices market, get a snapshot of the report Connected Drug Delivery Devices Market Trends - https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Growing Prevalence of Chronic Diseases Accelerates Market Demand
The growing global incidence of chronic conditions-including diabetes, asthma, COPD, and cardiovascular diseases-remains one of the primary catalysts for market expansion. These long-term diseases require continuous monitoring, precise dosing, and strict adherence to therapeutic schedules. Connected devices such as smart insulin pens, inhalers, and wearable injectors play a pivotal role in improving patient compliance, reducing dosing errors, and providing clinicians with reliable real-world data on treatment progress.

Diabetes especially represents a key application area for connected drug delivery. Over 591 million people globally were estimated to be living with diabetes in 2025, a figure projected to exceed 854 million by 2050. Increased adoption of connected insulin pens, automated insulin delivery (AID) systems, and Bluetooth-enabled continuous glucose monitors (CGMs) has become essential in enhancing glycemic management and personalized care.

Similarly, with more than 263 million people worldwide affected by asthma, connected inhalers and add-on inhaler sensors are transforming respiratory disease management by tracking inhaler technique, medication adherence, and usage patterns that help predict exacerbation risk.

To read more about the latest highlights related to Connected Drug Delivery Devices, get a snapshot of the key highlights entailed in the Connected Drug Delivery Devices Insights - https://www.delveinsight.com/sample-request/connected-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Digital Health & Remote Patient Monitoring Fuel Market Uptake
The rapid global shift toward digital health ecosystems-including telemedicine, remote patient monitoring (RPM), mobile health apps, and AI-integrated clinical decision systems-has strongly accelerated the adoption of connected drug delivery devices. These platforms enable patients and healthcare providers to exchange real-time therapeutic data, reduce unnecessary hospital visits, and streamline the management of chronic conditions in homecare settings.
Smart connected devices sync seamlessly with digital platforms to generate automated reminders, dose-tracking alerts, and adherence reports. Bluetooth remains the dominant connectivity technology, projected to account for 64% of the market in 2024, due to its low power consumption, broad compatibility with smartphones, and high reliability in real-time data transmission.

Integrated Connected Devices Dominate Product Landscape
Among product categories, Integrated Connected Devices-including smart inhaler devices and connected injectable devices-are expected to hold the largest segment share in 2024, accounting for nearly 60% of the global market. The widespread adoption of connected injectable devices, particularly for chronic conditions requiring long-term self-administration such as diabetes, rheumatoid arthritis, and multiple sclerosis, continues to support this growth.

These devices offer advanced features such as:
• Automated dose recording
• Bluetooth and NFC integration
• App-based analytics
• Real-time alerts for missed or incorrect doses
• AI-enabled insights for therapy optimization
Ongoing innovation is also accelerating adoption. For example, in 2024 Medtronic received FDA clearance for enhancements to its InPenTM app, introducing missed meal dose detection to improve insulin adherence.

Which MedTech key players in the Connected Drug Delivery Devices market are set to emerge as the trendsetter explore @ Key Connected Drug Delivery Devices Companies - https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Connected Drug Delivery Devices Regional Outlook: North America Leads, Asia-Pacific Accelerates
North America: Largest Market Share in 2024
North America is expected to dominate the global connected drug delivery devices market in 2024, supported by:
• Highly developed healthcare infrastructure
• Strong integration of digital health technologies
• High prevalence of chronic diseases
• Significant reimbursement support
• Presence of leading device manufacturers
More than 38.4 million U.S. adults have diabetes, fueling demand for smart insulin pens, automated pumps, and wearable injectors. Regulatory bodies such as the FDA provide streamlined pathways for digital health approvals, enabling rapid commercialization of connected therapeutics.

European Connected Drug Delivery Devices Market: Strong Digital Health Integration
Europe is expected to hold the second-largest market share. Key growth factors include:
• EMA and EU support for digital therapeutics
• Rising diabetes and asthma prevalence
• Initiatives such as Germany's DiGA reimbursement framework
• Cross-border health data exchange through the European Health Data Space (EHDS)

Asia-Pacific Connected Drug Delivery Devices Market: Fastest-Growing Region
Asia-Pacific is projected to be the fastest-growing regional market, driven by:
• Large patient population
• Increasing digital health adoption
• Government-led modernization of healthcare systems
• Rising chronic disease burden, particularly diabetes (China's diabetic population exceeds 140 million)
Countries such as China, India, Japan, and South Korea are experiencing rapid uptake of connected devices integrated with mobile health platforms and telemedicine services.

Interested in knowing how the Connected Drug Delivery Devices market will grow by 2032? Click to get a snapshot of the Connected Drug Delivery Devices Market Analysis - https://www.delveinsight.com/sample-request/connected-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Connected Drug Delivery Devices Competitive Landscape: Moderately Concentrated and Innovation-Driven
The connected drug delivery devices market is moderately concentrated, with key players leveraging heavy R&D investments, digital integration, strategic partnerships, and product launches to secure competitive advantage. Leading companies include:
• Findair Sp. z o. o.
• Adherium
• Propeller Health
• West Pharmaceutical Services, Inc.
• BIOCORP
• Phillips-Medisize
• Merck KGaA
• Novo Nordisk A/S
• Medtronic
• Tandem Diabetes Care, Inc.
• Ypsomed
• Teva Pharmaceutical Industries Ltd.
• Elcam Medical
• Cohero Health, Inc.
• BD
Startups specializing in AI-enabled sensor technology and digital adherence platforms are increasing competitive intensity and expanding innovation across the market.

Recent Industry Developments in Connected Drug Delivery Devices
• April 2025: Dexcom received FDA clearance for the G7 15-Day sensor, enabling extended wear and improved accuracy for diabetes monitoring.
• March 2025: Enable Injections obtained CE-mark approval for the enFuse Syringe Transfer System, supporting at-home biologic therapy administration.
• December 2024: FDA granted tentative approval for Lasix ONYU, a home-use micropump for heart failure-associated fluid overload.
• January 2024: BIOCORP received FDA 510(k) clearance for SoloSmart, a smart cap add-on for Sanofi insulin pens.

Request for sample report @ https://www.delveinsight.com/sample-request/connected-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

About the Connected Drug Delivery Devices Market Report
The comprehensive global report includes detailed segmentation by product type, technology, end user, and geography, offering strategic insights into market dynamics, competitive landscape, regulatory developments, and emerging opportunities. It supports stakeholders in identifying market potential, shaping organizational strategies, and capitalizing on the rapid growth of digital therapeutics and connected care technologies.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.